{
    "clinical_study": {
        "@rank": "8226", 
        "acronym": "DB4", 
        "arm_group": [
            {
                "arm_group_label": "SER120 750 ng", 
                "arm_group_type": "Experimental", 
                "description": "SER120 750 ng"
            }, 
            {
                "arm_group_label": "SER120 1500 ng", 
                "arm_group_type": "Experimental", 
                "description": "SER120 1500 ng"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the efficacy and safety of SER120 nasal spray formulations in patients with\n      nocturia"
        }, 
        "brief_title": "Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Nocturia", 
        "condition_browse": {
            "mesh_term": "Nocturia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female 50 years or older\n\n          -  Nocturia of 6 or more months duration averaging greater than 2 nocturic episodes per\n             night\n\n        Exclusion Criteria:\n\n          -  CHF\n\n          -  Diabetis Insipidus\n\n          -  Renal insufficiency\n\n          -  Hepatic insufficiency\n\n          -  Incontinence\n\n          -  Illnesses requiring systemic steroids\n\n          -  Malignancy within the past 5 years\n\n          -  Sleep apnea\n\n          -  Nephrotic syndrome\n\n          -  Unexplained pelvic mass\n\n          -  Urinary bladder neurological dysfunction\n\n          -  Urinary bladder surgery or radiotherapy\n\n          -  Pregnant or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01900704", 
            "org_study_id": "SPC-SER120-DB4-201301"
        }, 
        "intervention": [
            {
                "arm_group_label": "SER120 750 ng", 
                "description": "SER120 750 ng", 
                "intervention_name": "SER120 750 ng", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "SER120 1500 ng", 
                "description": "SER120 1500 ng", 
                "intervention_name": "SER120 1500 ng", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "contact": {
                "email": "sfein@serenitypharma.com", 
                "last_name": "Seymour Fein, MD", 
                "phone": "845-639-6760", 
                "phone_ext": "17"
            }, 
            "facility": {
                "address": {
                    "city": "New City", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10956"
                }, 
                "name": "Serenity R & D"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of nocturic episodes at the end of treatment compare to prior to treatment", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01900704"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Patient reported outcomes on the treatment", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "source": "Serenity Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Serenity Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}